Drug Trial Radar · NCT07449689
Comparing Acotiamide and Itopride for the Management of Indigestion
Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
368
Planned (sponsor's estimate)
Start
Apr 2026
Primary completion
Dec 2026
Study completion May 2027
Sponsor
- Lead sponsor
- Aga Khan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Searle Company Limited Pakistan
- First posted
- Mar 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blinded trial that will compare the effectiveness of two medications, acotiamide and itopride, in treating Functional Dyspepsia. Functional Dyspepsia causes uncomfortable symptoms arising from the gastro-duodenal region, such as fullness after meals, early satiation, stomach pain, and burning. The primary aim of this trial is to determine whether acotiamide is superior to itopride-specifically by a margin of 15%-at improving these meal-related digestive symptoms. Participants will be involved in the study for a total of 5 weeks. The study begins with a 7-day baseline period where participants will track their symptoms daily. Following the baseline period, participants will be randomly assigned to receive either 100mg of acotiamide three times a day or 50mg of itopride three times a day. The treatment phase will last for 4 weeks, during which participants will take the medication before meals on an empty stomach. Participants will continue to track their symptoms daily and will complete questionnaires about their overall treatment effect and quality of life at follow-up visits.
Conditions
- Functioanl Dyspepsia
- Post Prandial Distress Syndrome
Interventions
AcotiamideDrug
100mg thrice daily, before meals on an empty stomach for 4 weeks.
itoprideDrug
50mg thrice daily, before meals on an empty stomach for 4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- : Overall Treatment Effect (OTE)Time frame: Week 1 and Week 4.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.